日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study

乐伐替尼联合帕博利珠单抗治疗既往接受过治疗的晚期胃癌、胆道癌或胰腺癌患者:II期LEAP-005研究结果

Ponz-Sarvisé, Mariano; Rha, Sun Young; Gomez-Roca, Carlos A; Ortega Morán, Laura; Gill, Sanjeev; Tortora, Giampaolo; Geva, Ravit; Saada-Bouzid, Esma; Santoro, Armando; Kim, Tae Won; Heudobler, Daniel; Dutcus, Corina E; Okpara, Chinyere E; Ghori, Razi; Zhang, Yiwei; Vajdi, Amir; Dettman, E J; Jin, Fan; Groisberg, Roman; Shapira-Frommer, Ronnie

Identification of microenvironment features associated with primary resistance to anti-PD-1/PD-L1 + antiangiogenesis in gastric cancer through spatial transcriptomics and plasma proteomics.

通过空间转录组学和血浆蛋白质组学鉴定与胃癌中抗PD-1/PD-L1+抗血管生成原发性耐药相关的微环境特征

Cousin Sophie, Guégan Jean-Philippe, Shitara Kohei, Palmieri Lola Jade, Metges Jean Philippe, Pernot Simon, Fukuoka Shota, Koyama Shohei, Nishikawa Hiroyoshi, Bellera Carine A, Adenis Antoine, Gomez-Roca Carlos A, Cassier Philippe Alexandre, Hollebecque Antoine, Cantarel Coralie, Kind Michèle, Soubeyran Isabelle, Vanhersecke Lucile, Bessede Alban, Italiano Antoine